[
  {
    "ts": "2025-11-05T13:13:56+00:00",
    "headline": "Merck (MRK): Valuation Insights After Upbeat Q3, Oncology Growth, and Strategic Funding Progress",
    "summary": "Merck (MRK) just announced a major deal with Blackstone Life Sciences, securing $700 million in funding to advance the development of its investigational cancer drug, sacituzumab tirumotecan. This fresh capital comes as Merck builds momentum with new product approvals and progress in expanding its pipeline. See our latest analysis for Merck. Merck’s share price has been on a bumpy ride this year, with recent funding and steady pipeline wins doing little to reverse the overall momentum. Total...",
    "url": "https://finance.yahoo.com/news/merck-mrk-valuation-insights-upbeat-131356284.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "4a52f5f1-cc90-304c-9826-e75b788bdd15",
      "content": {
        "id": "4a52f5f1-cc90-304c-9826-e75b788bdd15",
        "contentType": "STORY",
        "title": "Merck (MRK): Valuation Insights After Upbeat Q3, Oncology Growth, and Strategic Funding Progress",
        "description": "",
        "summary": "Merck (MRK) just announced a major deal with Blackstone Life Sciences, securing $700 million in funding to advance the development of its investigational cancer drug, sacituzumab tirumotecan. This fresh capital comes as Merck builds momentum with new product approvals and progress in expanding its pipeline. See our latest analysis for Merck. Merck’s share price has been on a bumpy ride this year, with recent funding and steady pipeline wins doing little to reverse the overall momentum. Total...",
        "pubDate": "2025-11-05T13:13:56Z",
        "displayTime": "2025-11-05T13:13:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-valuation-insights-upbeat-131356284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-valuation-insights-upbeat-131356284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T13:00:00+00:00",
    "headline": "Quebec Expands Public Funding for CAPVAXIVE®",
    "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the province of Quebec has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to their publicly funded adult immunization program. This addition makes the vaccine available to eligible residents in accordance with the province's eligibility criteria, helping to increase access to pneumococcal immunization.",
    "url": "https://finance.yahoo.com/news/quebec-expands-public-funding-capvaxive-130000795.html",
    "source": "CNW Group",
    "provider": "yfinance",
    "raw": {
      "id": "bd056504-2f0f-3b54-ad24-bb7b686d2a4b",
      "content": {
        "id": "bd056504-2f0f-3b54-ad24-bb7b686d2a4b",
        "contentType": "STORY",
        "title": "Quebec Expands Public Funding for CAPVAXIVE®",
        "description": "",
        "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the province of Quebec has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to their publicly funded adult immunization program. This addition makes the vaccine available to eligible residents in accordance with the province's eligibility criteria, helping to increase access to pneumococcal immunization.",
        "pubDate": "2025-11-05T13:00:00Z",
        "displayTime": "2025-11-05T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/cnwgroup.com/513ff00319a0dceee275af483170f1ee",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8AGcLzfXdmHjay3zblb2Kg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/cnwgroup.com/513ff00319a0dceee275af483170f1ee.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FRzSvxwPLlv91QVhNp9JzQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/513ff00319a0dceee275af483170f1ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CNW Group",
          "url": "http://www.newswire.ca/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/quebec-expands-public-funding-capvaxive-130000795.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/quebec-expands-public-funding-capvaxive-130000795.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T11:52:08+00:00",
    "headline": "MSD secures $700m for broad-cancer ADC asset",
    "summary": "The funds will fuel continued Phase III clinical development of TROP-2 inhibitor sac-TMT.",
    "url": "https://www.pharmaceutical-technology.com/news/msd-secures-700m-for-broad-cancer-adc-asset/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "cbb8f21c-8303-381d-90c7-617f8d156c9a",
      "content": {
        "id": "cbb8f21c-8303-381d-90c7-617f8d156c9a",
        "contentType": "STORY",
        "title": "MSD secures $700m for broad-cancer ADC asset",
        "description": "",
        "summary": "The funds will fuel continued Phase III clinical development of TROP-2 inhibitor sac-TMT.",
        "pubDate": "2025-11-05T11:52:08Z",
        "displayTime": "2025-11-05T11:52:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/63bebc2b19de536a25dfb314852a51ce",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/spuguNaB3HWsYejYueH4Tw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/63bebc2b19de536a25dfb314852a51ce.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e.nS6OHv75ltrCGgQBxRTA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/63bebc2b19de536a25dfb314852a51ce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/msd-secures-700m-for-broad-cancer-adc-asset/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/msd-secures-700m-broad-cancer-115208866.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T11:30:00+00:00",
    "headline": "This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?",
    "summary": "Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter.",
    "url": "https://www.fool.com/investing/2025/11/05/this-company-now-has-the-worlds-1-drug-should-you/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "6e33cc9a-ad94-315d-af9f-d07c485837c8",
      "content": {
        "id": "6e33cc9a-ad94-315d-af9f-d07c485837c8",
        "contentType": "STORY",
        "title": "This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?",
        "description": "",
        "summary": "Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter.",
        "pubDate": "2025-11-05T11:30:00Z",
        "displayTime": "2025-11-05T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/c93322caee68cd60d7e378826eec5ead",
          "originalWidth": 1400,
          "originalHeight": 787,
          "caption": "Researchers in a healthcare lab.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vQaFXbVrdqwTtTiCGTAeYg--~B/aD03ODc7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/c93322caee68cd60d7e378826eec5ead.cf.webp",
              "width": 1400,
              "height": 787,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Eu5F7MJKGGf.XrYaJxbS2A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c93322caee68cd60d7e378826eec5ead.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/05/this-company-now-has-the-worlds-1-drug-should-you/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/company-now-worlds-no-1-113000051.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]